Meta-analysis reveals comparable efficacy and adverse events for rituximab and cyclosporine in idiopathic membranous nephropathy treatment, suggesting individualized care.
Rituximab is comparable in efficacy to cyclophosphamide and cyclosporine for IMN treatment, with no significant difference in remission rates or severe adverse events. Treatment should be individualized.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: